By P. Martiat, J.L. Michaux, and J. Rodhain for the Groupe FranGais de Cytogenetique Hematologique To better understand the Philadelphia-negative (Ph-) chronic myeloid leukemia (CML) and its relationships with Philadelphia-positive (Ph') CML and chronic myelomonocytic leukemia (CMML), a study was undertaken by the Groupe Franpais de Cytogenetique Hematologique. Thirty-five Ph-CML patients were investigated and compared with 55 chronic phase Ph+ CML and 100 CMML patients. There were 12 M-BCR positive (M-BCR') and 23 M-BCR negative (MBCR-) patients. No clinical or biologic differences were found between Ph' and Ph-, M-BCR+ patients. In the Ph-group, M-BCR' and M-BCR-patients differed significantly in age (47.7 f 6.6 v 67.0 f 6.1 years, respectively; P = .OOl), leukocytosis (153.4 f 135.1 v 58.5 f 37.7 IO'IL, P = .002), relative monocytosis (1.8% f 1.2% v 5.6% 2 1.4%, P = .048), absolute basophilia (8.5 f 9.7 v 0.9 f 1.5 10'lL. P = .001), percentage of immature myeloid precursors (IMP) in peripheral blood (29.0% f 9.5% v 15.3% f 8.1%,P = .001), and percentage of erythroblasts in bone marrow (BM) (6.5% f 3.5% v VER THE LAST 10 years an increasing number of 0 investigator~'-'~ have focused on the Philadelphia chromosome-negative (Ph-) chronic myeloid leukemia (CML). These patients do not have a Ph chromosome but a proportion of them, varying according to the selection criteria, have a rearrangement within the major breakpoint cluster region (M-BCR). Using different criteria (clinical, morphologic, or molecular), there have been many controversies about the existence of an entity called atypical chronic myeloid leukemia (aCML) that would cover the patients lacking a Ph chromosome and a rearrangement within M-BCR, and about whether this disorder should be regarded as distinct from CML and from chronic myelomonocytic leukemia (CMML). ' However, due to heterogeneity in the criteria used for ph-patients2.4.6.10.13,14 and due to the large diversity in the clinical and biologic presentation of CMML,'','',l6 there is room for debate on this subject.
Therefore, we undertook a study on Ph-CML to better understand this disorder, and to try to answer the question of whether Ph-M-BCR-CML should be regarded as a defined entity or as a subset of CMML.
MATERIALS AND METHODS

Patients.
Between December 1988 and March 1990, all patients referred to the participating centers with a tentative diagnosis of Ph-CML were included in this study, provided that they met five inclusion criteria as the initial diagnosis material: (1) absence of the Ph chromosome on analysis of at least 25 bone marrow (BM) and peripheral blood mitoses; (2) persistent, unexplained leukocytosis greater than 20.109/L; (3) more than 75% of peripheral white blood cells (WBC) belonging to the granulocytic lineage; (4) a peripheral blast cell percentage equal or less than 5%; and (5) presence of immature myeloid precursors (IMP) (promyelocytes, myelocytes, and metamyelocytes) in peripheral blood.
Patients with another chronic myeloproliferative syndrome (polycythemia vera,I7 essential thrombocythemia,'* idiopathic myelofibrosis, chronic neutrophilic leukemia, chronic myeloproliferative syndrome with hypereosinophilia) and patients whose peripheral monocytosis and marrow blast percentage make them meet the 14.6% f 3.6%. P = .OOl). Karyotypic abnormalities other than the Ph chromosome occurred in 0 of 12 M-BCR' at diagnosis and 7 of 23 M-BCR-Ph-CML (P = .033). None of the 13 investigated BCR-patients had detectable BCRIABL transcripts using polymerase chain reaction (PCR) and none had an N-RAS mutation. Cytologic findings showed a marked morphologic difference between M-BCR' and M-BCR-patients, especially in the monocytic lineage. Dysmyelopoietic features in CMML and M-BCR-patients were very similar, and the differences were of quantitative order only. Using four criteria (monocytosis, percentage of IMP, basophilia, and percentage of erythroblasts in BM), patients could be divided into typical and atypical CML and this classification correlated well with molecular findings. We conclude that, while Ph-, M-BCR', and Ph+ CML are identical diseases, Ph-, M-BCR-CML, and CMML have many similarities and might be only different aspects of a same entity. o 1991 by The American Society of Hematology.
French-American-British (FAB) criteria for CMML" were excluded from analysis.
Seven cases studied in previous years and that met the criteria of this study were also included, provided initial material was available for investigation.
The Ph-CML patients were compared with 55 consecutive Pht, M-BCR', CML patients in chronic phase referred to one of the institutions (UCL, Brussels, Belgium) between 1985 and 1990 and with 100 CMML patients included in another prospective study of our group.I5
The following parameters were investigated: (1) clinical: age, sex, and organomegaly; (2) hematologic: hemoglobin, platelet count, WBC count, differential count on at least 300 cells, immature precursors in the peripheral blood, and BM cytology; ( 3 ) biologic: neutrophil alkaline phosphatase (NAP) and serum lysozyme; (4) cytogenetic: peripheral blood and BM; and (5) molecular: presence or absence of M-BCR rearrangement at the genomic level, polymerase chain reaction (PCR) studies on RNA in patients whose material was available for the detection of the BCR1ABL hybrid message and N-RAS mutations.
Survival analysis was performed using the method of Kaplan and Meier.*'
Morphology. The pretreatment blood films and BM aspirates were first evaluated in each center, and were subsequently reviewed by a team of morphologists (G.F., Hopital St Louis, Paris, France; M.Z., CHRU Lille, France; and J.R., UCL Brussels, Belgium) without previous knowledge of the clinical, cytogenetic, and molecular findings. The presence of dysmyelopoietic features in BM cells and their severity were assessed using standard criteria.'' In addition, iron stains were performed in all patients to exclude refractory anemia with ringed sideroblasts. BM biopsies, available in all but one patient at diagnosis, were reviewed to rule out idiopathic myelofibrosis.
Chromosome studies were performed on peripheral blood and BM cells cultured for 24 to 48 hours without mitogens. Metaphases were G-banded with Wright's stain or trypsin technique and R-banded with heating techniques. A minimum of 25 metaphases were analyzed and classified according to the ISCN guidelines. The karyotypes of all patients were first reviewed in subgroup meetings of the Groupe FranGais de Cytogenktique Hkmatologique (GFCH). Karyotypic abnormalities raising problems were reviewed a second time during general workshops of the same group.
DNA analysis. High molecular weight DNA was prepared and restriction digested with at least three restriction enzymes according to standard protocols.z1 After electrophoresis on a 0.8% agarose gel and transfer to nylon membrane, the DNA was hybridized to either a probe covering most of the M-BCR sequences (universal probe) or to two probes 3' and 5' in M-BCR. In seven M-BCR-patients, N-RAS mutations (codons 12,13, and 61) were sought for using the polymerase chain reaction (PCR) and specific oligo-nucleotide hybridization according to the method described by Cogswell et al."
Total RNA was extracted from samples of 13 M-BCR nonrearranged patients, reverse transcribed, and submitted to PCR for the detection of hybrid BCR-ABL transcripts (e,a2, b,a,, and b,a,) as previously described by the participating cen-
ters.2z-24
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RESULTS
Patients.
The records of 42 patients were addressed for inclusion. After morphologic review, two patients had to be excluded because of a peripheral blastosis greater that 5%. Four patients were reclassified as CMML. Another patient had to be excluded because cytogenetic data were not available at diagnosis.
No patient had evidence of standard or variant t(9;22). There were seven chromosomal abnormalities at diagnosis that are detailed in Table 1 , part B. In three patients, the karyotype became abnormal during evolution of the disease. After classifying the patients into M-BCR' and M-BCR-, the analysis showed that no M-BCR' patient had karyotypic abnormalities at diagnosis (two became abnormal in blastic crisis), whereas seven abnormal karyotypes were found at diagnosis in the M-BCR-group (another patient also became abnormal in blastic crisis) ( Table 2) .
Twelve of 35 patients had a rearrangement within M-BCR and 23 were negative. Among the latter, 13 could be screened for the presence of a hybrid BCR/ABL transcript using PCR. PCR was performed to try to detect a rearrangement occurring within the BCR gene but downstream to M-BCR, which could lead to the formation of the typical message, as seen in a few Ph' CML.25,26 None of them were shown to be positive. Among the seven M-BCR-patients who were tested for possible N-RAS mutations, none was positive.
Clinical and morphologic studies. Clinical, biologic, and hematologic parameters were studied after classifying the patients into two (M-BCR' and M-BCR-) groups and
Cytogenetics.
DNA and RNA analysis. compared using the Mann-Whitney test. M-BCR' patients were also compared with the 55 Ph' CML patients, and the M-BCR-group with the 100 CMML patients.
The details of this comparison are shown in Table 3 . The first comparison between Ph-, M-BCR' and Ph-, M-BCR-patients showed six parameters differing significantly: age (years): 47.7 -I-6.6 versus 67.0 f 6.1, respectively, P = .001; leukocytosis: 153.4 109/L t 135.1 versus 58.5 10y/L f 37.7, P = .002; relative monocytosis: 1.8% & 1.2% versus 5.6% f 2.8%, P = .048; absolute basophilia: 8.5 109/L 9.7 versus 0.9 109/L 2 1.5, P = .001; percentage of IMP in PB: 29.0% f 9.5% versus 15.3% 2 8.1%, P = .001; and the percentage of erythroblasts in bone marrow:
6.5% f 3.5% versus 14.6% ? 3.6%, P = .001. There were no differences with respect to spleen size, absolute monocytosis, hemoglobin level, platelet count, serum lysozyme level, and NAP score.
In Ph-, M-BCR' patients, dysmyelopoiesis was mild. The most frequently observed abnormalities were a maturative defect of the granulocyte granules and nuclear abnormalities (nonlobulated nucleus) in the megakaryocytic lineage. The monocytic lineage did not show any maturative defect.
In the Ph-, M-BCR-group, dysgranulopoiesis was more pronounced, nuclear abnormalities being associated with a maturative defect of the granules, and there were nuclear abnormalities in the monocytic series. Megakaryocytic lineage was less severely involved and the percentage of nuclear abnormalities was less than 15%. These observations are summarized in Table 4 .
When comparing the Ph' and Ph-, M-BCR' patients, no significant differences with respect to the investigated parameters could be found.
Interestingly, the comparison between the Ph-, M-BCRand the CMML patients showed significant differences in relative (5.6% C 1.4% v 31.4% f 19.2%, P < .001) and absolute (3.3 10y/L f 2.1 v 10.9 109/L f 7.3, P = .036) monocytosis, absolute basophilia (0.9 109/L zt 1.5 v 0.07 1 0 9 / L t 0.8, P < .001), and percentage of IMP in PB (15.3% t 8.1% v 3.1% t 2.3%, P = .001). As far as age, sex ratio, spleen size, leukocytosis, platelet count, hemoglobin level, and percentage of BM erythroblasts were concerned, there were no differences between these two groups of patients. There were no qualitative differences for dysmyelopoiesis, but the fraction of dysplastic cells of the erythroid and megakaryocyte lineage was much more important in CMML, as was the number of patients involved (Table 4) .
Survival. The median survival of the Ph-, M-BCR' patients was not reached at 58 months. In the M-BCRcohort, the median survival was 36 months, which was not significantly different from the median of 30 months observed for the 100 CMML patients.
DISCUSSION
Our study confirms the similarity of Ph' and Ph-M-BCR' CML, which is in good agreement with previously published reports focusing on the correlation between molecular and cytologic The comparison between Ph-, M-BCR+ and Ph-, M-BCR-patients shows that these two disorders are different entities: they differ significantly in age, total WBC count, relative monocytosis, absolute basophilia, percentage of immature precursors in peripheral blood, and percentage of erythroblasts in BM (a finding that is equivalent to the lower mye1oid:erythroid ratio already reported by Ezdinli et ai2'). NAP score was not helpful in our experience and this is in agreement with the findings of Kantarjian et a1. 8 In their study, Shepherd et al' found that three entities (typical CML or CGL, atypical CML, and CMML) could be defined using morphologic criteria: morphology of granulocytes, monocytosis, absolute basophil count, and the number of mature and immature granulocytes in PB. When we tried to apply these criteria to our series (Table 5) , we found a good, though not perfect, correlation between the morphologic features and the molecular findings: four M-BCR-patients satisfied the CGL criteria while the aCML (19 patients) group contained only M-BCR-patients; this is in agreement with two previously published studie~.'~,'~ However, when we added the percentage of erythroblasts in bone marrow to these criteria ( < 15% for typical CML) we found a perfect agreement between the molecular findings and the cytologic features. Several group^^^^,','^^'^ have already focused on that correlation, but with some differences. In these studies, there remained a few patients who had either typical CML features without Table 3 . For personal use only. on October 30, 2017. by guest www.bloodjournal.org From Future studies of the underlying molecular abnormalities in this little subset of patients will certainly be of great interest, as these studies can give clues to mechanisms involved in the generation of CML. Cytogenetics was also of some help in discriminating these two groups of patients: while none of the Ph-, M-BCR' patients had karyotypic abnormalities at diagnosis, 7 of 23 M-BCR-had an abnormal karyotype. This difference was statistically significant. This frequency of abnormalities also is in good agreement with most of reported data.11,13.14 In their study of four Ph-, M-BCR+ patients, van der Plas et alZ2 found two abnormalities that could be considered Ph variant translocations, while in the two remaining cases karyotype was normal at diagnosis and the abnormalities occurred later on in the evolution, as usual in Ph' CML. The study by Kantarjian et aI8 does not segregate the abnormalities according to the molecular status.
The most striking finding to us was the similarity of the Ph-, M-BCR-patients and the 100 CMML patients used for comparison. They were identical as far as age, sex ratio, spleen size, survival, hemoglobin, platelet count, and my-e1oid:erythroid ratio were concerned. Due to the heterogeneity of the therapies used, survival data have only an indicative value. Of course, there were significant differences (total WBC count, basophilia, high percentage of IMP in PB and monocytosis), but the study itself by its design could have produced these differences. While the 100 CMML patients were selected only on the basis of the FAB criteria for myelodysplastic syndromes (MDS),I9 the criteria of this Ph-CML study required a high percentage of granulocytes (which excludes the possibility for the monocytosis to be as high as in unselected CMML) and the presence of IMP in PB (which obviously results in a higher percentage than in the CMML group). In our study on CMML, we found a significant percentage of patients having characteristics (high number of IMP and basophils in PB) classically related to typical CML. Although not systematically investigated in all patients, it seems worth mentioning that 2 of 10 M-BCR-patients had a monoclonal peak, a finding that has been reported in CMML.'53'6 The frequency and type of cytogenetic abnormalities were very similar to what is described in CMML,'2*15,'6 except that no deletion of chromosome 7 (7q-/-7) was found in this study. Two patients (nos. 24 and 30) had an abnormality of the long arm of chromosome 5 (5q31), one of which, [t(5;12)(q3l;pl2-13)], has been reported only once in a CMML case.*' Taking all these facts into account, we indulge on speculating that CMML and so-called Phatypical CML might be two aspects of the same disorder, with a tendency for atypical CML to express in a more balanced way between the granulocytic and the monocytic lineage. This opinion is supported by two other studies: Cogswell et all' also speculated that atypical CML could be regarded as a subgroup of CMML, and Kurzrock et all3 reported that the evolution of M-BCR-patients was quite close to what could be expected in CMML.
In conclusion, our study confirms the good correlation between molecular, clinical, and morphologic findings in Ph-CML, especially if the mye1oid:erythroid ratio in BM is taken into account, and also raises the question of whether Ph-, M-BCR-CML should continue to be regarded as an entity distinct from CMML.
